Chapter

Nephrogenic systemic fibrosis

Teresa K. Chen and Derek M. Fine

in Rheumatology and the Kidney

Second edition

Published on behalf of Oxford University Press

Published in print April 2012 | ISBN: 9780199579655
Published online February 2013 | e-ISBN: 9780191763472 | DOI: http://dx.doi.org/10.1093/med/9780199579655.003.0170

Series: Oxford Clinical Nephrology Series

Nephrogenic systemic fibrosis

Show Summary Details

Preview

1. NSF can be a devastating disorder resulting in excruciating pain and/or severe disability. 2. Gadolinium triggers NSF. 3. Not all GBC agents are created equal. Risk of NSF is dependent on the individual stability of each GBC agent. 4. The prolonged half-life of GBC agents in renal failure (GFR <30 ml/min/1.73m2) predisposes to NSF by allowing for dissociation of toxic free gadolinium. 5. The deposition of gadolinium in tissue triggers a cascade of events culminating in the clinical presentation of NSF. 6. Treatments for NSF are limited and still being investigated. Until then, our best defence against NSF is prevention. 7. For those with NSF, physical and occupational therapy are critical in maintaining functional status.

Chapter.  5288 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.